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Abstract 
The serine/threonine kinases ROCK1 and ROCK2 are central mediators of 
actomyosin contractile force generation that act downstream of the RhoA small GTP-
binding protein. As a result, they have key roles in regulating cell morphology and 
proliferation, and have been implicated in numerous pathological conditions and 
diseases including hypertension and cancer. Here we describe the generation of a 
gene-targeted mouse line that enables CRE-inducible expression of a conditionally-
active fusion between the ROCK2 kinase domain and the hormone-binding domain 
of a mutated estrogen receptor (ROCK2:ER). This two-stage system of regulation 
allows for tissue-selective expression of the ROCK2:ER fusion protein, which then 
requires administration of estrogen analogues such as tamoxifen or 4-
hydroxytamoxifen to elicit kinase activity. This conditional gain-of-function system 
was validated in multiple tissues by crossing with mice expressing CRE recombinase 
under the transcriptional control of cytokeratin14 (K14), murine mammary tumor 
virus (MMTV) or cytochrome P450 Cyp1A1 (Ah) promoters, driving appropriate 
expression in the epidermis, mammary or intestinal epithelia respectively. Given the 
interest in ROCK signaling in normal physiology and disease, this mouse line will 
facilitate research into the consequences of ROCK activation that could be used to 
complement conditional knockout models.  
 
Introduction 
The actomyosin cytoskeleton provides the physical structure that determines cell 
morphology; dynamic changes in cytoskeleton architecture are responsible for 
alterations in cell shape, adhesion, migration and division. Members of the Rho 
family of small molecular weight GTP-binding proteins (Rho GTPases) are key 
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regulators of cytoskeleton organization (Olson, 2016; Sadok and Marshall, 2014). 
Filamentous actin (F-actin) fibers associate with myosin motor proteins that 
hydrolyze ATP to power cytoskeletal contractile force generation (Geeves, 2016). 
Amongst the most important mediators of Rho GTPase signaling that influence 
contractile force are the serine/threonine kinases ROCK1 and ROCK2, which 
phosphorylate myosin regulatory light chains leading to increased myosin ATPase 
activity and consequent association with F-actin (Geeves, 2016; Julian and Olson, 
2014; Rath and Olson, 2012). 
There has been considerable interest in the biological functions of the ROCK 
kinases because of their apparent promise as chemotherapeutic targets in a variety 
of diseases and pathological conditions. The first described ROCK inhibitor Y27632 
was discovered based on its ability to reverse agonist-induced contraction of smooth 
muscle, including aortic, mesenteric and coronary artery tissue samples, and to 
lower the blood pressure of hypertensive rats (Uehata et al., 1997). Fasudil is a 
potent ROCK inhibitor, and has been routinely used in Japan to reduce the risk of 
cerebral vasospasm associated with subarachnoid hemorrhage (Satoh et al., 2014).  
It has also been suggested that ROCK inhibitors could be used for cancer therapy to 
reduce primary tumor growth and to combat metastatic dissemination (Olson, 2008; 
Rath and Olson, 2012). Recently, a multi-AGC kinase inhibitor AT13148 that has 
been in Phase I clinical testing was shown to be a potent ROCK inhibitor with anti-
tumor activity that also blocked melanoma cell migration and metastasis in vivo 
(Sadok et al., 2015; Yap et al., 2012).  
Complete knockouts of Rock1 or Rock2 revealed important roles in the 
movement of epithelial sheets necessary for eyelid and ventral body wall closure and 
for the closure of umbilical rings (Shimizu et al., 2005; Thumkeo et al., 2005). Mice 
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that allow for the conditional knockout of Rock1 or Rock2 have been generated and 
used to examine how ROCK1 contributes to specific biological processing including 
reactive fibrosis in response to heart pressure overload (Zhang et al., 2006) and 
insulin receptor signaling (Lee et al., 2009). By combining conditional deletion of 
Rock1 and Rock2, it was determined that together they make essential contributions 
to cell cycle progression, and have redundant and obligatory roles in non-small cell 
lung cancer and melanoma (Kümper et al., 2016). These loss-of-function 
approaches can be very informative about the requirement for ROCK signaling in 
various contexts, and help to predict and validate the effect of inhibitor 
administration. 
As a complement to loss-of-function systems or the use of pharmacological 
inhibitors to study ROCK signaling, we constructed conditionally-active forms of 
ROCK1 and ROCK2 by fusing the kinase domains with the hormone-binding domain 
of the estrogen receptor (ER) (Croft et al., 2005; Croft et al., 2004; Croft and Olson, 
2006a). By treating cells with estrogen analogues including tamoxifen or 4-
hydroxytamoxifen (4HT), it is possible to switch on ROCK2:ER fusion protein activity 
in a time and dose-dependent manner (Croft and Olson, 2006a). This conditional 
activation system has been used to study ROCK signaling and consequent 
actomyosin contractility in cell lines in vitro and in vivo (Croft et al., 2005; Croft et al., 
2004; Croft and Olson, 2006a; Croft and Olson, 2006b; Kumar et al., 2012; Sanz-
Moreno et al., 2011). The isolated kinase domains used in the ER-fusion proteins are 
similar to the fragments produced by caspase (Coleman et al., 2001) or granzyme B 
mediated proteolysis (Sebbagh et al., 2005), as well as examples of truncated 
protein products that result from somatic mutations in human tumors (Lochhead et 
al., 2010). To examine the role of ROCK activation in vivo, we generated a 
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genetically engineered mouse line in which expression of a ROCK2:ER fusion 
protein was driven by the cytokeratin 14 (K14) promoter (Samuel et al., 2009). 
Conditional activation of ROCK2:ER was sufficient to induce epidermal hyperplasia 
and the conversion of chemically-induced cutaneous papillomas to invasive 
carcinomas (Samuel et al., 2011) and also to accelerate the healing of full thickness 
skin wounds (Kular et al., 2015). 
To extend the utility of the conditionally-active ROCK2:ER system for gain-of-
function studies including in development, we generated a genetically modified 
mouse line by targeting the Hypoxanthine phosphoribosyltransferase (Hprt) locus on 
the X chromosome with a construct in which ROCK2:ER transgene transcription 
from an artificial chicken actin gene (CAG) promoter (Niwa et al., 1991) is dependent 
on CRE recombinase-mediated removal of a quadruple SV40 polyadenylation 
sequence transcriptional “stop” cassette flanked by loxP sites (Jackson et al., 2001). 
By crossing with mice expressing CRE recombinase from a K14 promoter, we found 
that it was possible in mouse epidermal keratinocytes to induce expression of the 
ROCK2:ER fusion protein that could then be conditionally activated with 4HT. This 
genetically modified mouse line will allow future studies aimed at characterizing the 
effects of ROCK gain-of-function in a tissue-specific manner to complement existing 
conditional Rock1 and Rock2 deletion mice.   
 
Results and Discussion 
To establish a conditionally active ROCK2 fusion protein (Figure 1A), a DNA 
sequence encoding the kinase domain (amino acids 5-553) of human ROCK2 was 
joined to that encoding enhanced green fluorescent protein (EGFP) at the 5’ end and 
an engineered version of the hormone binding domain of the estrogen receptor (ER) 
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at the 3’ end, modified to include a G525R replacement that greatly reduces binding 
of 17β estradiol, to prevent activation by circulating estrogenic hormone, while 
retaining binding of 4HT (Danielian et al., 1993) to allow activation by exogenous 
ligands. When treated with 4HT, conditional ROCK2:ER activation leads to the 
phosphorylation of substrates including the regulatory myosin light chains (MLC), the 
myosin binding subunit (MYPT) of the MLC phosphatase complex and LIM kinases 1 
and 2 (LIMK1/2), which collectively results in actomyosin contractile force generation 
(Croft and Olson, 2006a). As a control for expression of the ROCK2:ER fusion 
protein that might have additional non-catalytic functions, we also made a kinase-
dead version (KD2:ER) that has a single amino acid mutation (K125G) that blocks 
ATP-binding and kinase catalytic activity (Croft and Olson, 2006a). 
 HM1 embryonic stem cells lack the promoter and first two exons of the Hprt 
locus on the X-chromosome (Selfridge et al., 1992). By targeting this locus with 
constructs containing flanking homology arms that include the human HPRT 
promoter and first exon as well as the second and third exon of mouse Hprt, it is 
possible to reconstitute a functional Hprt gene that enables positive selection of 
successful recombinants in hypoxanthine-aminopterin-thymidine (HAT) medium 
(Bronson et al., 1996). In this way, we were able to specifically target the ROCK2:ER 
transgene to the Hprt locus (Figure 1B). 
 To allow for conditional expression of ROCK2:ER, the fusion protein coding 
sequence was cloned downstream of a synthetic promoter (CAG) consisting of a 
cytomegalovirus early enhancer element, a chicken β-actin gene promoter with the 
first exon and intron, and a splice acceptor (SA) from the rabbit β-globin gene (Niwa 
et al., 1991), followed by a loxP-Stop-loxP (LSL) transcriptional stop cassette (Figure 
1B). The inclusion of quadruple SV40 derived polyadenylation signals (Stop) within 
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this cassette leads to the premature termination of transcription, until CRE-mediated 
recombination of the loxP sites removes the Stop cassette to allow transcription to 
proceed (Figure 1C). By crossing with mice expressing CRE recombinase from 
tissue selective promoters, it would be possible to restrict ROCK2:ER expression to 
targets of choice, thereby enabling for determination of the consequences of ROCK 
activation in a site-specific manner. 
  To validate the inducibility of ROCK2:ER expression in vivo, LSL-ROCK2:ER 
mice were intercrossed with mice expressing a fusion protein comprising CRE 
recombinase and the hormone binding domain of the progesterone receptor (PR) 
under the control of the K14 promoter (Figure 2A), which allows for conditional CRE 
activation by ligands including RU486 (Berton et al., 2000) and expression of the 
ROCK2:ER fusion protein. Subsequent treatment with 4-hydroxytamoxifen would 
then activate the expressed ROCK2:ER fusion protein (Figure 2A). Polymerase 
chain reaction (PCR) analysis of DNA isolated from ear skin that had been topically 
treated with RU486 (2 µg in 20 µl ethanol per ear for 1 week) demonstrates the CRE 
and ligand-dependent recombination of LSL-ROCK2:ER (Figure 2B). In all cases, a 
LSL-ROCK2:ER 575 base pair (bp) PCR product was visible (Figure 2B, top and 
bottom panels), while a 600 bp CRE:PR transgene product was evident in the 4 
positive samples (Figure 2B, middle panel). Only in the presence of both CRE:PR 
and RU486 treatment was there loxP-Stop-loxP recombination that led to the 
production of a 500 bp ROCK2:ER band (Figure 2B, lower panel). Furthermore, 
immunohistochemical (IHC) staining of untreated or RU486 treated ear skin with 
antibodies against EGFP (Figure 2C) or ROCK2 (Figure 2D) revealed ROCK2:ER 
expression restricted to the epidermal layer following CRE:PR stimulation with 
RU486. In mouse skin treated with RU486 to permit ROCK2:ER expression, the 
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additional topical application of 4HT (330 µg in 20 µl solution in ethanol) resulted in 
inCREased phosphorylation of the ROCK substrate MYPT1 on T696 (pMYPT1) 
(Figure 2E). Further confirmation of the CRE-dependent expression of ROCK2:ER 
was obtained by crossing LSL-ROCK2:ER mice with a mouse line that expressed 
constitutively active CRE from a K14 promoter (Dassule et al., 2000) (Figure 2F). 
When keratinocytes were isolated from mouse tails and cultured in vitro as we 
previously described (Samuel et al., 2011), western blotting of cell lysates revealed 
that ROCK2:ER expression in LSL-ROCK2:ER mice was only observed in the 
presence of K14-CRE, similar to the ROCK2:ER expression in the K14-ROCK2:ER 
positive control keratinocytes (Samuel et al., 2009). Similar to previous observations 
(Croft et al., 2004), treatment with 1 µM 4HT increased the levels of ROCK2:ER 
protein in K14-CRE; LSL-ROCK2:ER and K14-ROCK2:ER keratinocytes (Figure 2F), 
likely through protein stabilization. These results confirm CRE-induced ROCK2:ER 
expression in LSL-ROCK2:ER mice in cytokeratin 14 positive epidermal 
keratinocytes. 
To further validate the tissue-specific inducibility and functionality of 
ROCK2:ER in target tissues, the LSL-ROCK2:ER and LSL-KD2:ER mice were 
separately crossed onto the Tg(MMTV-CRE)4Mam/J (MMTV-CRE) (Wagner et al., 
1997) and Tg(Cyp1a1-CRE)1Dwi (Ah-CRE) (Ireland et al., 2004) strains, which 
express CRE recombinase within the mammary and intestinal epithelia respectively 
(Figure 3A, 4A). These crosses yielded the further strains MMTV-CRE; LSL-
ROCK2:ER, MMTV-CRE; LSL-KD2:ER, Ah-CRE; LSL-ROCK2:ER and Ah-CRE; 
LSL-KD2:ER. To determine whether ROCK2:ER could be expressed and 
conditionally activated within the mammary epithelium, twice weekly intra-peritoneal 
injections of tamoxifen (60 mg/kg body weight in corn oil) were administered to 
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cohorts of 8 week old LSL-ROCK2:ER, LSL-KD2:ER, MMTV-CRE; LSL-ROCK2:ER 
and MMTV-CRE; LSL-KD2:ER mice. Mice were sacrificed 24 hours after the final 
injection and sections derived from formalin-fixed paraffin-embedded mammary 
tissue were subjected to immunofluorescence analysis, revealing expression of the 
ROCK2:ER or KD:ER fusion proteins in MMTV-CRE; LSL-KD2:ER and MMTV-CRE; 
LSL-ROCK2:ER tissues (Figure 3B), accompanied by enhanced phosphorylation of 
the ROCK target MYPT1 at T696 in MMTV-CRE; LSL-ROCK2:ER mouse mammary 
epithelium but not in the MMTV-CRE; LSL-KD2:ER tissue (Figure 3C).  
To determine whether ROCK2:ER could be expressed and conditionally 
activated within the intestinal epithelium, four intra-peritoneal injections of β-
Naphthoflavone (80 mg/kg body weight per injection) were administered to cohorts of 
8 week old Ah-CRE; LSL-KD2:ER and Ah-CRE; LSL-ROCK2:ER mice over 48 hours 
to induce intestine-specific CRE recombinase expression. Four days following the 
final injection of β-Naphthoflavone, mice were injected intraperitoneally with 
tamoxifen (60 mg/kg body weight in corn oil), with a further injection of tamoxifen a 
week later. Mice were sacrificed 24 hours after the final injection and sections 
derived from formalin-fixed paraffin-embedded intestinal tissue were subjected to 
immunofluorescence analysis, revealing enhanced phosphorylation of the ROCK 
target MYPT1 at T696 in Ah-CRE; LSL-ROCK2:ER mouse intestinal epithelium and 
not in the Ah-CRE; LSL-KD2:ER tissues (Figure 4B). Taken together, these results 
demonstrate that LSL-ROCK2:ER mice inducibly express conditionally-active 
ROCK2 in a tissue-specific manner. 
As a test of the consequences of conditional ROCK2 activation in the whole 
mouse, LSL-ROCK2:ER and LSL-KD2:ER mice were separately crossed with 
Tg(CAG-cre/Esr1*)5Amc (CAG-CRE:ER) (Hayashi and McMahon, 2002) mice that 
Page 9 of 28
John Wiley & Sons, Inc.
genesis
This article is protected by copyright. All rights reserved.
10 
 
undergo CRE-mediated recombination in most tissues in response to tamoxifen 
treatment (Figure 5A). When mice were administered tamoxifen citrate in their 
drinking water (100 µg/mL) to induce CRE-mediated recombination and ROCK2:ER 
fusion protein activation, 6/6 CAG-CRE:ER; LSL-ROCK2:ER mice died within 7 
days, while all tamoxifen treated CAG-CRE:ER; LSL-KD2:ER and untreated CAG-
CRE:ER; LSL-ROCK2:ER mice survived over this time period (Figure 5B). When 
brains were dissected and examined histologically, it became apparent that all 
tamoxifen treated CAG-CRE:ER; LSL-ROCK2:ER mice had evidence of cerebral 
hemorrhagic lesions that were not observed in tamoxifen treated CAG-CRE:ER; 
LSL-KD2:ER (Figure 5C). These results suggest that there would be potential for the 
CAG-CRE:ER; LSL-ROCK2:ER transgenic mouse line to be used as an inducible 
cerebral stroke model. 
Although loss-of-function genetically-modified mice have been useful in 
determining how specific targets may make essential contributions to various 
biological processes, there is also considerable value in gain-of-function (GoF) 
systems. Rather than inferring how a given protein might be involved from a loss of 
effect, GoF mutants can be used to determine biological roles by observing direct 
positive effects. We have described a GoF system that allows for the conditional 
activation of ROCK2 activity in a tissue selective manner, which has a wide-variety of 
potential applications for the study of tissue homeostasis and function, as well as in 
models of pathological conditions and diseases including cancer.  
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Methods 
Animal models 
Conditional LSL-ROCK2:ER and control LSL-KD2:ER mice were constructed by 
targeting loxP-Stop-loxP ROCK2:ER or KD2:ER transgenes under the transcriptional 
control of a CAG promoter by gene-targeting each to the Hprt locus using an 
approach we have previously described (Samuel et al., 2009; Schachtner et al., 
2012). The CAG loxP-Stop-loxP transgene was made by first replacing the SA 
region of the plasmid pBigT (gift of Frank Costantini; Addgene plasmid 21270) 
(Srinivas et al., 2001) with the chimeric synthetic promoter CAG (Niwa et al., 1991) 
from the plasmid pTurbo-CRE (a gift from Prof. Tim Ley, The Genome Center at 
Washington University, St. Louis, USA). The 3-phosphoglycerate kinase (PGK) 
promoter and EM7 promoter sequence from pL452 were then inserted into 
pBigT.CAG by recombineering in E. coli (Liu and Bambara, 2003). Short 5′ and 3′ 
homology arms from the Hprt targeting plasmid pSKB1 (Bronson et al., 1996) were 
placed flanking the expression cassette to generate pHprt.CAG.loxP-STOP-loxP. 
ROCK2:ER or KD2:ER fusion protein cDNAs were then cloned downstream of the 
loxP-Stop-loxP (LSL) transcriptional termination cassette. The transgene was then 
recombineered into pSKB1 (Bronson et al., 1996) to generate the final targeting 
pHprt-CAG-LSL-ROCK2:ER or pHprt-CAG-LSL-KD2:ER vectors. 
The targeting vector was linearized and transferred into Hprt-deficient HM1 
embryonic stem (ES) cells (Magin et al., 1992) by electroporation, which were then 
cultured on DR4 mouse embryonic fibroblast feeder layers (Tucker et al., 1997). 
Recombinants were selected in HAT supplement containing medium (Sigma) and 
appropriate targeting of the Hprt locus on 5′ and 3′ sides was confirmed by PCR 
using genomic DNA template prepared from HAT-resistant colonies. Genotyping 
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used the ExpandTM Long Template PCR system (Roche) according to the 
manufacturer's instructions. Primer pairs for genotyping the targeted ES cells were 5′ 
GTTGCTGAGGCAAAAATAGTGTAAT and CCATTTACCGTAAGTTATGTAACGC 
and 3′ CTACCTAGTGAGCCTGCAAACTG and 
ATGTAAGTGCTAGGAATTGAACCTG. 
 Following identification of correctly targeted clones, mouse lines were derived 
by injection into C57BL/6J blastocysts according to standard protocols (Nagy et al., 
2003). Germline transgene transmission was identified by inspection of progeny coat 
colour and confirmed by PCR. 
All procedures were performed under appropriate licenses and according to 
the UK Home Office guidelines or under approval granted by the SA 
Pathology/CALHN Animal Ethics Committee and according to Australian Code for 
the Care and Use of Animals for Scientific Purposes, 8th edition (2013). Mouse lines 
described herein will be made available to the research community. 
 
Polymerase chain reaction (PCR) 
2.5 µl of genomic DNA was used as a template in a 25 µI reaction volume containing 
2.5 mM MgCl2, 0.5 µM reverse and forward primers for each transgene, 0.25 mM 
dNTPs and 1 unit Taq DNA polymerase (1 U/µl) in a 200 µl PCR tube. PCR was 
performed for each transgene in a thermal cycler. Electrophoresis was performed on 
the PCR products using 1% agarose gels that were stained with ethidium bromide. 
ROCK2 primers: Forward CGACCACTACCAGCAGAACA; Reverse 
GACGAACCAACTGCACTTCA. K14-CRE:PR primers: Forward 
CGGTCGATGCAACGAGTGAT; Reverse CCACCGTCAGTACGTGAGAT.  
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Keratinocyte isolation and culture 
Primary keratinocytes were extracted from tail skin as described previously (Samuel 
et al., 2011). Cells were maintained at 37°C, with 5% CO2 and 3% O2, in keratinocyte 
growth medium (KGM-2; Lonza) and 50 µM Ca2+ on collagen-1 coated dishes (10 
µg/mL; Advanced BioMatrix 5005). 
 
Small molecules 
 4-Hydroxytamoxifen (Sigma H7904), RU486 (Sigma M8046), β-Naphthoflavone 
(Sigma N3633), tamoxifen (Sigma T5648), tamoxifen citrate salt (Sigma T9262). 
 
Immunoblotting 
Standard protocols were used for Western blot analysis. Whole cell lysates were 
prepared in cell lysis buffer (1% SDS (w/v), 50 mM Tris pH 7.5) and protein 
concentration was determined by bicinchoninic assay (Sigma). ROCK1/2 (Millipore 
07-1458) or GFP (Abcam ab6556) primary antibodies were used at 1:500 dilution. 
Alexa-Fluor 680-conjugated (Thermo Fisher Scientific) secondary antibody was 
detected by infrared imaging (Li-Cor Odyssey). 
 
Immunohistochemistry and immunofluorescence analysis 
Formalin-fixed, paraffin-embedded sections were rehydrated and immersed in 10 
mM citric acid buffer at pH 6.0, boiled for 20 min, cooled, and sequentially blocked 
with 3% H2O2 and 10% normal goat serum in PBS. Sections were then incubated 
with primary antibody, followed by incubation with Envision + System-HRP labeled 
Polymer (Dako). Primary antibodies were routinely used at 1:50 or 1:100 dilutions. 
Staining was visualized with Liquid DAB + Substrate (Dako). Immunofluorescence 
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analysis was carried out as for immunohistochemistry, eliminating the peroxide 
blocking step. HRP-labeled secondary antibodies were replaced by Alexa Fluor 488 
(green) or 594 (red)-conjugated secondary antibodies (Thermo Fisher Scientific) and 
slides were mounted in VECTASHIELD mounting medium (Vector Labs). Primary 
antibodies used: ROCK2 (Santa Cruz SC-5561), GFP (Clontech 632377), pMYPT1 
(Thr696; Millipore ABS45), cytokeratin 14 (Leica Biosystems). Photomicrographs 
were obtained with a Zeiss microscope and Axiovision image capture software. 
Immunofluorescence images were acquired using an LSM 700 confocal system 
(Zeiss) or using a Leica SCN 400f scanner and Leica Slidepath Digital Hub software, 
respectively. 
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Figure Legends 
Figure 1. Targeting a conditionally-active loxP-Stop-loxP ROCK2:ER transgene to 
the Hprt locus. (A) The conditionally-active ROCK2:ER fusion protein is inactive in 
the absence of ligand. Upon stimulation with estrogen analogues including 4-
hydroxytamoxifen (4HT), the specific activity of the kinase domain of ROCK2 
increases leading to phosphorylation of substrates including MYPT1, MLC and LIM 
kinases 1 and 2 (LIMK1/2), which results in the generation of actomyosin contractile 
force. EGFP = enhanced green fluorescent protein. ER = modified hormone binding 
domain of the estrogen receptor. (B) The Hprt locus in mouse HM1 embryonic stem 
cells lacks a promoter and first two exons, allowing for targeting by the homology 
arms of the pHprt-CAG-LSL-ROCK2:ER plasmid that includes a promoter and first 
exon of human HPRT (yellow) and second exon of mouse Hprt. Successful targeting 
and homologous recombination reconstitutes an active Hprt locus that allows for 
positive selection with HAT medium. (C) By crossing with mice expressing CRE 
recombinase from tissue-selective promoters, CRE-mediated recombination 
between loxP sites removes the transcription termination cassette (STOP) to allow 
ROCK2:ER transgene expression. 
 
Figure 2. Validation of LSL-ROCK2:ER expression in mouse skin. (A) LSL-
ROCK2:ER mice were crossed to a line expressing a CRE fusion with the hormone-
Page 20 of 28
John Wiley & Sons, Inc.
genesis
This article is protected by copyright. All rights reserved.
21 
 
binding domain of the progesterone receptor (PR) from a K14 promoter. Treatment 
with the progesterone ligand RU486 enables recombination and consequent 
ROCK2:ER expression. Stimulation with 4-hydroxytamoxifen then stimulates 
ROCK2:ER catalytic activity. (B) PCR analysis of the ROCK2:ER and CRE 
transgenes in mouse ear skin without or with RU486 treatment. Unrecombined LSL-
ROCK2:ER results in the production of a 575 bp PCR band in all samples, while a 
600 bp CRE:PR is seen only in the 4 transgene expressing mice. Following RU486 
treatment, recombination resulted in the production of a 500 bp PCR band, indicating 
dependence on both CRE expression and RU486 treatment. (C, D) Validation of 
LSL-ROCK2:ER recombination and consequent ROCK2:ER expression in mouse 
skin following topical RU486 treatment by EGFP or ROCK2 immunohistochemical 
staining. Scale bar = 100 µm. (E) Treatment with RU486 does not lead to increased 
MYPT1 phosphorylation (pMYPT1) unless combined with topical 4HT treatment to 
conditionally activate ROCK2:ER. (F) Validation of LSL-ROCK2:ER expression in 
epidermal keratinocytes following crossing with K14-CRE expressing mice. Primary 
keratinoctyes were isolated from the tails of mice with LSL-ROCK2:ER alone, LSL-
ROCK2:ER plus K14-CRE or K14-ROCK2:ER as indicated. A ROCK2:ER protein 
band was only detected by blotting with ROCK2 or GFP antibodies in keratinocytes 
from LSL-ROCK2:ER plus K14-CRE or positive control K14-ROCK2:ER mice. 
Consistent with previous observations, treatment with 4HT increased ROCK2:ER 
protein levels relative to untreated cells. 
 
Figure 3. Validation of LSL-ROCK2:ER expression in mouse mammary epithelium. 
(A) LSL-ROCK2:ER and LSL-KD2:ER mice were crossed separately onto a strain 
expressing a CRE recombinase under the control of the MMTV promoter. Mice will 
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express the ROCK2:ER or KD2:ER fusion protein constitutively, but transgene-
derived ROCK will not be activated until systemic treatment with tamoxifen, which is 
metabolized to 4HT and activates ROCK2:ER but not kinase-dead KD2:ER. (B) 
Immunofluorescence analysis of mammary tissues derived from LSL-KD2:ER, LSL-
ROCK2:ER, MMTV-CRE; LSL-KD2:ER or MMTV-CRE; LSL-ROCK2:ER mice 
showing expression of the EGFP:KD2:ER or EGFP:ROCK2:ER fusion proteins in 
CRE-expressing mice. Scale bars = 50 µm (C) Immunofluorescence analysis 
(cytokeratin 14 [white in monochromatic panels and red in Merge] to mark basal 
mammary epithelium and pMYPT1 [white in monochromatic panels and green in 
Merge]) of mammary tissue derived from LSL-KD2:ER, LSL-ROCK2:ER, MMTV-
CRE; LSL-KD2:ER and MMTV-CRE; LSL-ROCK2:ER mice that have been treated 
systemically with tamoxifen, showing elevated phosphorylation of MYPT1 in CRE-
expressing LSL-ROCK2:ER mammary epithelium but not LSL-KD2:ER expressing 
tissues. Scale bars = 50 µm. 
 
Figure 4. Validation of LSL-ROCK2:ER expression in mouse intestinal epithelium. 
(A) LSL-ROCK2:ER and LSL-KD2:ER mice were crossed to a line expressing a CRE 
recombinase under the control of the cytochrome P450 Cyp1A1 (Ah) promoter. Mice 
will express the ROCK2:ER or KD2:ER fusion protein upon activation of the Cyp1A1 
promoter by systemic treatment with β-Naphthoflavone, but transgene-derived 
ROCK will not be activated until systemic treatment with tamoxifen, which is 
metabolized to 4HT and activates ROCK2:ER. (B) Immunofluorescence analysis 
(pMYPT1 [green]) of intestinal epithelium derived from Ah-CRE; LSL-KD2:ER and 
Ah-CRE; LSL-ROCK2:ER mice that have been treated systemically with tamoxifen, 
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showing elevated phosphorylation of MYPT1 in CRE-expressing LSL-ROCK2:ER 
intestinal epithelium but not LSL-KD2:ER tissues. 
 
Figure 5. Consequence of conditional activation of ROCK2:ER in whole mice. (A) 
LSL-ROCK2:ER and LSL-KD2:ER mice were crossed to a line expressing a CRE:ER 
fusion recombinase under the control of an artificial chicken actin gene (CAG) 
promoter. Mice express the ROCK2:ER or KD2:ER fusion protein in a tamoxifen-
induced manner in most tissues. Systemic treatment with tamoxifen, which is 
metabolized to 4HT, activates ROCK2:ER but not KD2:ER fusion protein. (B) 
Survival curves for CAG-CRE:ER; LSL-ROCK2:ER and CAG-CRE:ER; LSL-KD2:ER 
mice that were untreated or treated with tamoxifen as indicated. Survival p-value 
determined by Mantel-Cox test (CAG-CRE:ER; LSL-ROCK2:ER untreated n = 3; 
CAG-CRE:ER; LSL-ROCK2:ER; tamoxifen treated n = 6:  CAG-CRE:ER; LSL-
KD2:ER untreated n = 3). (C) Brain sections from tamoxifen treated CAG-CRE:ER; 
LSL-KD2:ER (left) and CAG-CRE:ER; LSL-ROCK2:ER (middle) mice. Scale bars = 1 
mm. Red and blue rectangle insets indicate sites of cerebral hemorrhagic lesions in 
the CAG-CRE:ER; LSL-ROCK2:ER image are shown at higher magnification at right 
with corresponding borders. Scale bars = 100 µm. 
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Figure 1. Targeting a conditionally-active loxP-Stop-loxP ROCK2:ER transgene to the Hprt locus. (A) The 
conditionally-active ROCK2:ER fusion protein is inactive in the absence of ligand. Upon stimulation with 
estrogen analogues including 4-hydroxytamoxifen (4HT), the specific activity of the kinase domain of ROCK2 
increases leading to phosphorylation of substrates including MYPT1, MLC and LIM kinases 1 and 2 
(LIMK1/2), which results in the generation of actomyosin contractile force. EGFP = enhanced green 
fluorescent protein. ER = modified hormone binding domain of the estrogen receptor. (B) The Hprt locus in 
mouse HM1 embryonic stem cells lacks a promoter and first two exons, allowing for targeting by the 
homology arms of the pHprt-CAG-LSL-ROCK2:ER plasmid that includes a promoter and first exon of human 
HPRT (yellow) and second exon of mouse Hprt. Successful targeting and homologous recombination 
reconstitutes an active Hprt locus that allows for positive staining with HAT medium. (C) By crossing with 
mice expressing CRE recombinase from tissue-selective promoters, CRE-mediated recombination between 
loxP sites removes the transcription terminationcassette (STOP) to allow ROCK2:ER transgene expression.  
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Figure 2. Validation of LSL-ROCK2:ER expression in mouse skin. (A) LSL-ROCK2:ER mice were crossed to a 
line expressing a CRE fusion with the hormone-binding domain of the progesterone receptor (PR) from a 
K14 promoter. Treatment with the progesterone ligand RU486 enables recombination and consequent 
ROCK2:ER expression. Stimulation with 4-hydroxytamoxifen then stimulates ROCK2:ER catalytic activity. 
(B) PCR analysis of the ROCK2:ER and CRE transgenes in mouse ear skin without or with RU486 treatment. 
Unrecombined LSL-ROCK2:ER results in the production of a 575 bp PCR band in all samples, while a 600 bp 
CRE:PR is seen only in the 4 transgene expressing mice. Following RU486 treatment, recombination resulted 
in the production of a 500 bp PCR band, indicating dependence on both CRE expression and RU486 
treatment. (C, D) Validation of LSL-ROCK2:ER recombination and consequent ROCK2:ER expression in 
mouse skin following topical RU486 treatment by EGFP or ROCK2 immunohistochemical staining. Scale bar 
= 100 µm. (E) Treatment with RU486 does not lead to increased MYPT1 phosphorylation (pMYPT1) unless 
combined with topical 4HT treatment to conditionally activate ROCK2:ER. (F) Validation of LSL-ROCK2:ER 
expression in epidermal keratinocytes following crossing with K14-CRE expressing mice. Primary 
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keratinoctyes were isolated from the tails of mice with LSL-ROCK2:ER alone, LSL-ROCK2:ER plus K14-CRE 
or K14-ROCK2:ER as indicated. A ROCK2:ER protein band was only detected by blotting with ROCK2 or GFP 
antibodies in keratinocytes from LSL-ROCK2:ER plus K14-CRE or positive control K14-ROCK2:ER mice. 
Consistent with previous observations, treatment with 4HT increased ROCK2:ER protein levels relative to 
untreated cells.  
Figure 2  
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Figure 3. Validation of LSL-ROCK2:ER expression in mouse mammary epithelium. (A) LSL-ROCK2:ER and 
LSL-KD2:ER mice were crossed separately onto a strain expressing a CRE recombinase under the control of 
the MMTV promoter. Mice will express the ROCK2:ER or KD2:ER fusion protein constitutively, but transgene-
derived ROCK will not be activated until systemic treatment with tamoxifen, which is metabolized to 4HT and 
activates ROCK2:ER but not kinase-dead KD2:ER. (B) Immunofluorescence analysis of mammary tissues 
derived from LSL-KD2:ER, LSL-ROCK2:ER, MMTV-CRE; LSL-KD2:ER or MMTV-CRE; LSL-ROCK2:ER mice 
showing expression of the EGFP:KD2:ER or EGFP:ROCK2:ER fusion proteins in CRE-expressing mice. Scale 
bars = 50 µm (C) Immunofluorescence analysis (cytokeratin 14 [white in monochromatic panels and red in 
Merge] to mark basal mammary epithelium and pMYPT1 [white in monochromatic panels and green in 
Merge]) of mammary tissue derived from LSL-KD2:ER, LSL-ROCK2:ER, MMTV-CRE; LSL-KD2:ER and MMTV-
CRE; LSL-ROCK2:ER mice that have been treated systemically with tamoxifen, showing elevated 
phosphorylation of MYPT1 in CRE-expressing LSL-ROCK2:ER mammary epithelium but not LSL-KD2:ER 
expressing tissues. Scale bars = 50 µm. 
              Figure 3  
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Figure 4. Validation of LSL-ROCK2:ER expression in mouse intestinal epithelium. (A) LSL-ROCK2:ER and 
LSL-KD2:ER mice were crossed to a line expressing a CRE recombinase under the control of the cytochrome 
P450 Cyp1A1 (Ah) promoter. Mice will express the ROCK2:ER or KD2:ER fusion protein upon activation of 
the Cyp1A1 promoter by systemic treatment with β-Naphthoflavone, but transgene-derived ROCK will not be 
activated until systemic treatment with tamoxifen, which is metabolized to 4HT and activates ROCK2:ER. (B) 
Immunofluorescence analysis (pMYPT1 [green]) of intestinal epithelium derived from Ah-CRE; LSL-KD2:ER 
and Ah-CRE; LSL-ROCK2:ER mice that have been treated systemically with tamoxifen, showing elevated 
phosphorylation of MYPT1 in CRE-expressing LSL-ROCK2:ER intestinal epithelium but not LSL-KD2:ER 
tissues.  
Figure 4  
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Figure 5. Consequence of conditional activation of ROCK2:ER in whole mice. (A) LSL-ROCK2:ER and LSL-
KD2:ER mice were crossed to a line expressing a CRE:ER fusion recombinase under the control of an 
artificial chicken actin gene (CAG) promoter. Mice express the ROCK2:ER or KD2:ER fusion protein in a 
tamoxifen-induced manner in most tissues. Systemic treatment with tamoxifen, which is metabolized to 
4HT, activates ROCK2:ER but not KD2:ER fusion protein. (B) Survival curves for CAG-CRE:ER; LSL-
ROCK2:ER and CAG-CRE:ER; LSL-KD2:ER mice that were untreated or treated with tamoxifen as indicated. 
Survival p-value determined by Mantel-Cox test (CAG-CRE:ER; LSL-ROCK2:ER untreated n = 3; CAG-
CRE:ER; LSL-ROCK2:ER; tamoxifen treated n = 6:  CAG-CRE:ER; LSL-KD2:ER untreated n = 3). (C) Brain 
sections from tamoxifen treated CAG-CRE:ER; LSL-KD2:ER (left) and CAG-CRE:ER; LSL-ROCK2:ER (right) 
mice. Scale bars = 1 mm. Red and blue rectangle insets indicate sites of cerebral haemorrhagic lesions in 
the CAG-CRE:ER; LSL-ROCK2:ER image are shown at higher magnification at right with corresponding 
borders. Scale bars = 100 µm.  
Figure 5  
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